VB119 for Kidney Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new treatment called VB119 to see if it is safe and effective. It focuses on people with a kidney condition called primary MN. Researchers want to understand how VB119 works in the body and if it can help these patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Who Is on the Research Team?
Keenan
Principal Investigator
ValenzaBio, Inc.
Are You a Good Fit for This Trial?
This trial is for adults with a confirmed diagnosis of primary Membranous Nephropathy (kidney disease) within the last 10 years, showing high levels of protein in urine. Participants must have stable blood pressure and agree to use effective contraception. Those with certain infections, diabetes, low white blood cell counts, or other autoimmune diseases like lupus are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of VB119 to evaluate safety and tolerability
Dose Expansion
Participants receive expanded doses of VB119 to further evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- VB119
Find a Clinic Near You
Who Is Running the Clinical Trial?
ACELYRIN Inc.
Lead Sponsor
Tenet Medicines
Lead Sponsor
ValenzaBio, Inc.
Lead Sponsor